fexapotide triflutate

June 7, 2017July 22, 2019

Enlarged Prostate Therapy Fexapotide Actually Improves Patients’ Sexual Function, Studies Show

News

Fexapotide triflutate improves the sexual functioning of men with an enlarged prostate, according to combined results of four Phase 3 clinical trials. The therapy’s developer, Nymox Pharmaceutical, had previously reported that Fexapotide ... Read more

May 5, 2017May 5, 2017

Nymox Seeks European Approval of Fexapotide Triflutate to Treat BPH Symptoms

News

Nymox Pharmaceutical is seeking British, Dutch, German and Spanish government authorization to market Fexapotide triflutate for the treatment of benign prostatic hyperplasia (BPH) symptoms. “Fexapotide has the real potential to alter the way ... Read more

December 17, 2015December 17, 2015

Topline Data from BPH Extension Studies Show Safety, Efficacy of Single-Injection Treatment

News

Nymox Pharmaceutical Corp. has announced that its long-term extension prospective double-blind Phase 3 clinical trials of fexapotide triflutate (NX-1207) as a single-injection treatment in benign prostatic hyperplasia (BPH) patients have met their primary ... Read more